A Phase 2 Open-label Study to Evaluate the Safety and Efficacy of VGT-309 a Tumor-Targeted Activatable Fluorescent Imaging Agent to Identify Cancer in Subjects Undergoing Lung Cancer Surgery

Recruiting
99 years or below
All
Phase 2
40 participants needed
1 Location

Brief description of study

To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of VGT-309 to detect cancer utilizing near-infrared (NIR) fluorescence and histopathology results. 1. Sensitivity: defined as the probability that the tissue fluoresces when it is cancer, as confirmed by histology (TP/(TP+FN)) 2. Specificity: defined as the probability that the tissue does not fluoresce when it is not cancerous as confirmed by histology (TN/(TN+FP)) 3. Positive predictive value (PPV): defined as the probability that a tissue sample contains cancer on histologic exam if it fluoresces (TP/(TP+FP)) 4. Negative predictive value (NPV): defined as the probability that the tissue sample does not contain cancer on histologic exam if it does not fluoresce (TN/(TN+FN)) For each of the defined Clinically Significant Events: A. Number of pulmonary nodules visualized using VGT-309 NIR imaging and confirmed histologically that would not otherwise be found by conventional modalities available to the surgeon. B. Number of subjects where at least one synchronous lesion is identified with VGT-309 NIR imaging, but not with conventional modalities available to the surgeon (white light, palpation, and/or pre-operative imaging), and it proves to be histologically cancer. C. Number of subjects where at least one positive margin is identified by VGT-309 NIR imaging and pathology demonstrates cancer cells within 5 mm of the margin.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 11 May 2022. Study ID: 850893

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center